|Bid||28.030 x 900|
|Ask||28.040 x 400|
|Day's Range||27.230 - 28.136|
|52 Week Range||8.580 - 28.136|
|PE Ratio (TTM)||1,336.43|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Exelixis, Inc.'s (EXEL) efforts to develop its pipeline and uptake in Cabometyx sales should be the key areas of focus when the company reports second-quarter results.
Which is the better growth stock going forward -- Exelixis or Incyte? It depends.
Sarepta Therapeutics Inc (NASDAQ:SRPT) Duchenne muscular dystrophy (DMD) drug Exondys 51 (eteplirsen) has outclassed expectation, leading the biotech firm to soar 20% yesterday in trading following a wow factor second-quarter earnings top-line performance. While consensus had been angling for Sarepta's second full quarter of Exondys 51 to yield $22.5 million, the firm powered through with a 114% quarterly rise to a hefty $35 million, leading management to boost full year 2017 guidance now for the second time in a year, rising from "exceeding 95 million" to an even more bullish range of $125 million to $130 million. William Blair analyst Tim Lugo highlights strong commercial trends that also led Sarepta to beat his own forecast of $20 million.